- Home
- PINE vs TVRD Comparison
PINE vs TVRD Comparison
Compare PINE & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | TVRD |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.7M | 246.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PINE | TVRD |
|---|---|---|
| Price | $17.00 | $4.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $17.67 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 163.1K | 123.7K |
| Earning Date | 10-23-2025 | 11-13-2025 |
| Dividend Yield | ★ 6.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $57,423,000.00 | N/A |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $2.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.81 | N/A |
| 52 Week Low | $13.10 | $3.74 |
| 52 Week High | $17.88 | $43.65 |
Technical Indicators
Market Signals| Indicator | PINE | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 57.43 | 34.35 |
| Support Level | $17.10 | $4.05 |
| Resistance Level | $17.88 | $4.71 |
| Average True Range (ATR) | 0.38 | 0.27 |
| MACD | -0.11 | 0.55 |
| Stochastic Oscillator | 23.73 | 73.20 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.